ISU Abxis said that the company’s U.S. partner Catalyst Biosciences has acquired a patent for its hemophilia B treatment, Dalcinonacog Alfa (DalcA), from the European Patent Office.
Catalyst Biosciences obtained orphan drug designation from European regulators in June 2017 and presented the interim results of phase 2 clinical trial at the European Association for Haemophilia and Allied Disorders (EAHAD) last year, ISU Absix said in a news release on Wednesday.
The U.S. company also completed the clinical trial phase 2b of DalcA last month and plans to present the final data of the clinical results within the first half of this year.
“The decision to register a patent for the treatment in Europe came after the company decided to expand its portfolio after registering the patent in the U.S., China, and Japan,” Catalyst Biosciences CEO Nassim Usman said. “With the recent completion of phase 2b clinical trial, we believe DalcA will be an appropriate strategy to treat hemophilia B.”
<© Korea Biomedical Review, All rights reserved.>